Elranatamab: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 28.04.2026. Verfasst von Mohamed Elmeliegy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Research and Development, Pfizer, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis. The recommended subcutaneous elranatamab dosing consists of fixed step‐up doses of 12 mg on day 1 and 32 mg on day 4 to mitigate the incidence and severity of cytokine release syndrome (CRS), followed by the full fixed dose of 76 mg once weekly (QW) from weeks 2 to 24. In responders, 76 mg QW is reduced to every 2 weeks (Q2W) after ≥ 6 QW cycles and to every 4 weeks after ≥ 6 Q2W cycles. The full dose (76 mg QW) results in a higher probability of achieving an objective response versus lower doses without worsening the safety profile. This regimen was based on the collective safety, efficacy, pharmacokinetic, and pharmacodynamic data from MagnetisMM‐1, ‐2, ‐3, and ‐9. In the pivotal MagnetisMM‐3 study, in patients with BCMA‐naive RRMM, elranatamab resulted in a 61.0% overall response rate; 37.4% achieved complete response or stringent complete response. Median duration of response was not yet reached; the probability of maintaining response at 30 months was 61.0%. Median progression‐free and overall survival were 17.2 and 24.6 months, respectively. In MagnetisMM‐3 patients, common adverse events (≥ 40%; any grade/grade 3/4) included infections (71.7%/38.5%), CRS (58.8%/0.5%), anemia (53.5%/42.2%), neutropenia (46.0%/44.4%), and diarrhea (42.8%/3.2%). Elranatamab demonstrated deep and durable responses, a manageable safety profile, and low‐grade CRS with predictable timing. Elranatamab is being further evaluated as monotherapy or combination therapy in earlier treatment lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Research and Development, Pfizer, Inc., San Diego, California, USA.
- Oncology Research and Development, Pfizer SLU, Madrid, Spain.
- Oncology Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.
- Pfizer Research & Development, Pfizer, Inc., San Diego, California, USA.
- Pfizer Research & Development, Pfizer, Inc., South San Francisco, California, USA.
ORCID-Profile: Mohamed Elmeliegy, Hoi-Kei Lon, Kamrine Poels
Förderung
- Pfizer
Zitieren
APA
Elmeliegy, M., Viqueira, A., Vandendries, E., Soltantabar, P., Lon, H. K., Poels, K., Shtylla, B., Irby, D., Bompiani-Myers, K., O'Brien, T., & Hibma, J. (2026). Elranatamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70554
Vancouver
Elmeliegy M, Viqueira A, Vandendries E, Soltantabar P, Lon HK, Poels K, et al. Elranatamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70554
BibTeX
@article{Elmeliegy2026,
author = {Elmeliegy, Mohamed and Viqueira, Andrea and Vandendries, Erik and Soltantabar, Pooneh and Lon, Hoi-Kei and Poels, Kamrine and Shtylla, Blerta and Irby, Donald and Bompiani-Myers, Kristin and O'Brien, Thomas and Hibma, Jennifer},
title = {Elranatamab: Mechanism of Action, Clinical, and Translational Science},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70554}
}
EUVIMED